Zurich, Feb 7, 2026, 19:55 CET — Market closed.
- Roche (ROG) closed at 356.40 Swiss francs on Friday, slipping 0.64%.
- Attention now turns to the Feb. 9 neurology investor webcast, which is linked to multiple sclerosis data.
- Roche’s dividend and the timing of its annual meeting are also on investors’ radar.
Roche slid 0.64% on Friday to finish at 356.40 Swiss francs, with no new headlines out to move the stock ahead of the weekend. Shares ranged from 352.50 to 357.20 francs, volume landing at roughly 766,000.
The Swiss bourse sits idle until Monday, so for now, traders are looking past Friday’s slip and focusing instead on potential catalysts coming up next week. Roche stands out as a name where sentiment can pivot sharply on fresh clinical data or pipeline news, regardless of broader market stillness.
On Jan. 29, Roche put out its full-year update, projecting mid single-digit sales growth for 2026 at constant exchange rates. Core earnings per share, the company said, should climb in the high single digits. The board is looking to bump the dividend up to 9.80 francs. “2025 was a strong year for Roche,” CEO Thomas Schinecker said, citing “significant momentum across our pharmaceutical pipeline.” Roche
Looking ahead to Monday, Roche has a virtual Neurology/ACTRIMS investor event set for Feb. 9, running from 16:30 to 17:30 CET. The lineup includes management alongside an outside expert.
Roche plans to spotlight its neurology pipeline in an upcoming webcast, with fresh results from the Phase III FENtrepid trial comparing fenebrutinib and Ocrevus (ocrelizumab) in people with primary progressive multiple sclerosis, or PPMS. PPMS is a type of MS that usually gets worse over time and doesn’t have as many obvious relapses as other MS forms.
It’s no coincidence: the ACTRIMS Forum in San Diego, set for Feb. 5-7, lands right when clinicians and investors will be focused on multiple sclerosis data.
Roche shares have proved quick to react to pipeline updates. According to a Jan. 29 Reuters piece, the stock climbed roughly 25% from mid-November, fueled by encouraging study results that bolstered faith in the company’s development efforts. Still, a softer U.S. dollar kept a lid on growth in overseas sales.
But there’s risk on the table, too. If Monday’s presentation doesn’t deliver fresh detail—or worse, sparks new worries about safety, how long the benefit actually lasts, or what the commercial rollout looks like—the stock could pull back, as investors might decide to take profits after the rally.
Roche isn’t just gearing up for a neurology update next week; there’s a key date for shareholders on the books, too. March 10 is circled for the annual general meeting, per the company’s investor site. Investors will vote on the dividend proposal and other matters.
Traders are set to scrutinize the Monday slide deck and webcast, zeroing in on how Roche positions fenebrutinib versus Ocrevus—and what that suggests for readout timelines. If anything unexpected turns up, it’ll likely hit Roche’s share price quickly once SIX trading starts back up.
